The protective effect of a DNA vaccine encoding the Toxoplasma gondii cyclophilin gene in BALB/c mice

Parasite Immunology

Volumn 35, Issue 3-4, 2013, Pages 140-146

  Gong, P ^a   Huang, X ^a   Yu, Q ^b   Li, Y ^a   Huang, J ^a   Li, J ^a   Yang, J ^a   Li, H ^a   Zhang, G ^a   Ren, W ^a   Zhang, X ^a  

^a JILIN UNIVERSITY   (China)

^b Jilin Provincial Center for Disease Prevention and Control   (China)

Author keywords

BALB c mice; Cycliophilin; DNA vaccine; Th1 response; Toxoplasma gondii

Indexed keywords

CYCLOPHILIN; TOXOPLASMA GONDII VACCINE;

ARTICLE; BAGG ALBINO MOUSE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL RATE; TACHYZOITE; TOXOPLASMA GONDII; TOXOPLASMOSIS; VACCINATION;

ANIMALS; ANTIBODIES, PROTOZOAN; CELL PROLIFERATION; CYCLOPHILINS; DISEASE MODELS, ANIMAL; FEMALE; INTERFERON-GAMMA; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; MALE; MICE; MICE, INBRED BALB C; PROTOZOAN VACCINES; SPLEEN; SURVIVAL ANALYSIS; TH1 CELLS; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL; VACCINES, DNA;

EID: 84873456971     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/pim.12024     Document Type: Article

References (35)

1. Joiner KA & Dubremetz JF. Toxoplasma gondii: a protozoan for the nineties. Infect Immun 1993; 61: 1169-1172.
2. Hill D & Dubey JP. Toxoplasma gondii: transmission, diagnosis and prevention. Clin Microbiol Infect 2002; 8: 634-640.
3. Black MW & Boothroyd JC. Lytic cycle of Toxoplasma gondii. Microbiol Mol Biol Rev 2000; 64: 607-623.
4. Dubey JP & Kirkbride CA. Toxoplasmosis and other causes of abortions in sheep from north central United States. J Am Vet Med Assoc 1990; 196: 287-290.
5. Dubey JP. Status of toxoplasmosis in sheep and goats in the United States. J Am Vet Med Assoc 1990; 196: 259-262.
6. Bhopale GM. Development of a vaccine for toxoplasmosis: current status. Microbes Infect/Institut Pasteur 2003; 5: 457-462.
7. Mateus-Pinilla NE, Dubey JP, Choromanski L & Weigel RM. A field trial of the effectiveness of a feline Toxoplasma gondii vaccine in reducing T. gondii exposure for swine. J Parasitol 1999; 85: 855-860.
8. Kur J, Holec-Gasior L & Hiszczynska-Sawicka E. Current status of toxoplasmosis vaccine development. Expert Rev Vaccines 2009; 8: 791-808.
9. Dubey JP & Jones JL. Toxoplasma gondii infection in humans and animals in the United States. Int J Parasitol 2008; 38: 1257-1278.
10. Dautu G, Munyaka B, Carmen G, et al. Toxoplasma gondii: DNA vaccination with genes encoding antigens MIC2, M2AP, AMA1 and BAG1 and evaluation of their immunogenic potential. Exp Parasitol 2007; 116: 273-282.
11. Fang R, Nie H, Wang Z, et al. Protective immune response in BALB/c mice induced by a suicidal DNA vaccine of the MIC3 gene of Toxoplasma gondii. Vet Parasitol 2009; 164: 134-140.
12. Li J, Huang X, Zhang G, Gong P, Zhang X & Wu L. Immune response and protective efficacy against homologous challenge in BALB/c mice vaccinated with DNA vaccine encoding Toxoplasma gondii actin depolymerizing factor gene. Vet Parasitol 2011; 179: 1-6.
13. Cui X, Lei T, Yang D, Hao P, Li B & Liu Q. Toxoplasma gondii immune mapped protein-1 (TgIMP1) is a novel vaccine candidate against toxoplasmosis. Vaccine 2012; 30: 2282-2287.
14. Fischer G & Aumuller T. Regulation of peptide bond cis/trans isomerization by enzyme catalysis and its implication in physiological processes. Rev Physiol Biochem Pharmacol 2003; 148: 105-150.
15. Matsuda S & Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 2000; 47: 119-125.
16. High KP, Joiner KA & Handschumacher RE. Isolation, cDNA sequences, and biochemical characterization of the major cyclosporin-binding proteins of Toxoplasma gondii. J Biol Chem 1994; 269: 9105-9112.
17. Aliberti J, Valenzuela JG, Carruthers VB, et al. Molecular mimicry of a CCR5 binding-domain in the microbial activation of dendritic cells. Nat Immunol 2003; 4: 485-490.
18. Tuo W, Fetterer R, Jenkins M & Dubey JP. Identification and characterization of Neospora caninum cyclophilin that elicits gamma interferon production. Infect Immun 2005; 73: 5093-5100.
19. Tuo W, Zhao Y, Zhu D & Jenkins MC. Immunization of female BALB/c mice with Neospora cyclophilin and/or NcSRS2 elicits specific antibody response and prevents against challenge infection by Neospora caninum. Vaccine 2011; 29: 2392-2399.
20. Vercammen M, Scorza T, Huygen K, et al. DNA vaccination with genes encoding Toxoplasma gondii antigens GRA1, GRA7, and ROP2 induces partially protective immunity against lethal challenge in mice. Infect Immun 2000; 68: 38-45.
21. Wang H, Liu Q, Liu K, et al. Immune response induced by recombinant Mycobacterium bovis BCG expressing ROP2 gene of Toxoplasma gondii. Parasitol Int 2007; 56: 263-268.
22. Huang X, Li J, Zhang G, Gong P, Yang J & Zhang X. Toxoplasma gondii: protective immunity against toxoplasmosis with recombinant actin depolymerizing factor protein in BALB/c mice. Exp Parasitol 2012; 130: 218-222.
23. Rinfret A, Collins C, Menard R & Anderson SK. The N-terminal cyclophilin-homologous domain of a 150-kilodalton tumor recognition molecule exhibits both peptidylprolyl cis-trans-isomerase and chaperone activities. Biochemistry 1994; 33: 1668-1673.
24. Triantafilou M & Triantafilou K. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol 2002; 23: 301-304.
25. Aliberti J, Reis e Sousa C, Schito M, et al. CCR5 provides a signal for microbial induced production of IL-12 by CD8 alpha+ dendritic cells. Nat Immunol 2000; 1: 83-87.
26. Behnke JM, Wahid FN, Grencis RK, Else KJ, Ben-Smith AW & Goyal PK. Immunological relationships during primary infection with Heligmosomoides polygyrus (Nematospiroides dubius): downregulation of specific cytokine secretion (IL-9 and IL-10) correlates with poor mastocytosis and chronic survival of adult worms. Parasite Immunol 1993; 15: 415-421.
27. Bessieres MH, Swierczynski B, Cassaing S, et al. Role of IFN-gamma, TNF-alpha, IL4 and IL10 in the regulation of experimental Toxoplasma gondii infection. J Eukaryot Microbiol 1997; 44: 87S.
28. Gazzinelli RT, Wysocka M, Hieny S, et al. In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4 + T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. J Immunol 1996; 157: 798-805.
29. Roberts CW, Ferguson DJ, Jebbari H, Satoskar A, Bluethmann H & Alexander J. Different roles for interleukin-4 during the course of Toxoplasma gondii infection. Infect Immun 1996; 64: 897-904.
30. Sher A, Denkers EY & Gazzinelli RT. Induction and regulation of host cell-mediated immunity by Toxoplasma gondii. Ciba Found Symp 1995; 195: 95-104; discussion 104-109.
31. Ibrahim HM, Bannai H, Xuan X & Nishikawa Y. Toxoplasma gondii cyclophilin 18-mediated production of nitric oxide induces Bradyzoite conversion in a CCR5-dependent manner. Infect Immun 2009; 77: 3686-3695.
32. Leyva R, Herion P & Saavedra R. Genetic immunization with plasmid DNA coding for the ROP2 protein of Toxoplasma gondii. Parasitol Res 2001; 87: 70-79.
33. Fachado A, Rodriguez A, Molina J, et al. Long-term protective immune response elicited by vaccination with an expression genomic library of Toxoplasma gondii. Infect Immun 2003; 71: 5407-5411.
34. Angus CW, Klivington-Evans D, Dubey JP & Kovacs JA. Immunization with a DNA plasmid encoding the SAG1 (P30) protein of Toxoplasma gondii is immunogenic and protective in rodents. J Infect Dis 2000; 181: 317-324.
35. Couper KN, Nielsen HV, Petersen E, Roberts F, Roberts CW & Alexander J. DNA vaccination with the immunodominant tachyzoite surface antigen (SAG-1) protects against adult acquired Toxoplasma gondii infection but does not prevent maternofoetal transmission. Vaccine 2003; 21: 2813-2820.